Diarrhea and generalized weakness in a patient with metastatic melanoma and a lumbosacral mass, after initiation of therapy with a checkpoint inhibitor: A case report

Abstract

Introduction: checkpoint inhibitors are immunomodulatory antibodies against cytotoxic t-lymphocyte-associated antigen [Ipilimumab] and Programmed cell death-1 receptor [nivolumab, pembrolizumab] that have improved the prognosis of patients with melanoma and non-squamous cell lung carcinoma. Despite their clinical benefit, these agents are associated with the development of immune-related adverse events (irAEs) of varying morbidity. these irAEs are clinically challenging to be diagnosed and to be treated, as described in this case report. case report: A 58-year old male presented with radicular pain, weakness and loss of sensation in his right leg, eleven years after treatment for cutaneous melanoma. A large lumbosacral mass found on spinal MrI and patient underwent local